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Abstract  Improvement  in  survival  of  patients  with  HCC  depends  on  detecting  small  lesions.
This is  possible  by  screening  all  patients  with  cirrhosis  for  HCC.  However,  these  small  lesions  are
difﬁcult to  characterise  as  only  50  to  80%  of  lesions  less  than  3  cm  have  a  typical  HCC  appear-
ance, depending  on  the  imaging  technique  used.  MRI,  with  its  various  possibilities  (dynamic
sequences,  diffusion-weighting,  liver-speciﬁc  contrast  agents),  is  currently  the  most  effectiveNon-invasive
diagnosis
imaging technique  for  characterising  these  small  HCCs,  but  at  present  we  do  not  know  the  best
combination  of  imaging  examinations  for  diagnosing  the  condition.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Hepatocellular  carcinoma  (HCC),  the  incidence  of  which  continues  to  increase  (11  cases
per  100,000  people  per  year  in  France),  has  become  the  ﬁfth  most  frequent  cancer  and
the  fourth  in  terms  of  mortality  in  the  world.  In  more  than  90%  of  cases  it  occurs  on  a
background  of  underlying  liver  disease  —– cirrhosis  or  a  chronic  liver  disease  [1—3].  Since
there  is  known  to  be  an  environment  favouring  the  occurrence  of  this  cancer,  monitoring
programmes  for  cirrhotic  patients  have  been  set  up  in  various  countries,  and  it  has  thus
been  shown  that  monitoring  improves  their  survival.  The  study  in  a  large  population  (18,816
patients)  by  Zhang  et  al.  [4]  showed  an  increase  in  survival  in  patients  whose  HCC  was
discovered  while  they  were  in  the  monitored  group  of  more  than  37%  compared  with
patients  in  the  group  which  was  not  monitored.  This  study  was  conﬁrmed  in  2008  by  Chan
et  al.  [5]  who,  in  1136  patients  with  HCC  with  cirrhosis,  showed  overall  survival  of  61.9
months  if  the  patients  had  been  monitored  before  the  discovery  of  their  HCC  and  11.6
months  if  the  patients  had  not  been  so  monitored.
In  France,  patients  at  risk  of  HCC  are  monitored  by  6-monthly  ultrasound  exami-
nations  [6].  Unfortunately,  it  is  insufﬁciently  prescribed  and  observed,  covering  only
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decision  can  be  taken  in  a  multidisciplinary  consultation,98  
bout  20%  of  the  target  population  [7],  but  can  lead  to  the
etection  of  small  HCC  (less  than  30  mm  or  even  20  mm).
hile  curative  treatment  can  be  offered  for  small  HCCs,
hich  have  a  signiﬁcantly  better  prognosis  than  larger  ones,
iagnosing  them  with  certitude  is  more  difﬁcult.  Charac-
erisation  of  a  nodule  in  cirrhosis  discovered  by  ultrasound
epends  on  contrast-enhanced  ultrasound,  CT  or  MRI.  Nev-
rtheless,  the  well-documented  characteristics  of  HCC  that
ermit  non-invasive  diagnosis  [3,8]  can  be  incomplete  for
mall  tumours  and  may  thus  pose  a  diagnostic  problem  that
an  detract  from  the  beneﬁt  of  its  having  been  detected
arly.  In  addition,  the  existence  of  pseudo-lesions  and  other
iver  tumours  is  more  often  a  source  of  confusion  for  small
CCs  than  it  is  for  larger  lesions.
The  aim  of  this  article  is  therefore  to  describe  the  typ-
cal  and  atypical  appearance  of  small  HCCs,  to  discuss  the
ifferential  diagnoses,  and  to  provide  the  technical  points
nd  signs  that  should  lead  to  HCC  being  suspected.
igure 1. Typical MRI appearance of hepatocellular carcinoma. Moni
RI in phase (a) and out of phase (b): hepatic steatosis [out-of-phase fa
njection in the arterial (c) and portal (d) phases: 16 mm lesion (arrow) e
w
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ypical appearance of hepatocellular
arcinoma
uring  its  evolution  from  the  regenerative  nodule  via  the
ysplastic  nodule  to  HCC,  the  vascularisation  of  the  nod-
le,  which,  like  all  the  liver  parenchyma,  is  initially  mainly
ortal,  gradually  becomes  arterial  by  tumour  neoangiogen-
sis,  the  portal  vascularisation  at  the  same  time  decreasing.
his  evolution  of  the  tumour  vasculature  results  in  the  two
ypical  aspects  of  the  image  of  hepatocellular  carcinoma:
arly  enhancement  in  the  arterial  phase  and  washout  of  the
esion  in  the  portal  or  late  phase  (Fig.  1).  In  a  cirrhotic  liver,
CC  can  be  diagnosed  non-invasively  on  the  basis  of  obser-
ation  of  these  features,  and  after  staging,  a  therapeutictoring examination for cirrhosis of exogenous origin. T1-weighted
ll in signal (b)]. T1-weighting with fat saturation after gadolinium
nhanced in the arterial phase and washed out in the portal phase.
ithout  recourse  to  biopsy  [3,8].
While  MRI  is  the  most  effective  technique  for  showing  this
ypical  appearance,  it  is  nevertheless  still  imperfect,  since
mall
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these  aspects  are  observed  in  less  than  60%  of  nodules  of  less
than  3  cm  [9—12].  The  sensitivity  of  the  different  techniques
for  diagnosing  small  HCC  is  shown  in  Table  1.  At  the  same
time,  the  speciﬁcity  of  the  imaging  techniques,  particularly
of  MRI,  is  high,  at  between  95  and  96%  in  the  literature,  and
false  positives  are  frequently  high-grade  dysplastic  nodules
[10],  treatment  of  which  is  probably  appropriate  because  of
the  high  risk  of  their  progressing  to  HCC  [13].  To  summarise,
when  a  small  nodule  is  found  in  liver  cirrhosis,  the  presence
of  the  typical  appearance  provides  virtual  certainty  of  HCC,
but  its  absence  does  not  mean  that  this  diagnosis  can  be
eliminated.
Diagnostic difﬁculties and features
providing answers
Atypical appearance of small hepatocellular
carcinomas
Absence  of  typical  vascular  kinetics
Although  less  frequently  hypervascular  in  the  arterial  phase
than  large  HCCs,  small  HCCs  retain  this  feature  in  the
vast  majority  of  cases  (75—85%).  On  the  other  hand,  the
absence  of  lesion  washout  in  the  portal  or  late  phase  is
common  (40—60%  of  cases  depending  on  the  technique
used)  [10—12].  Lesion  washout  is  most  frequently  absent
in  contrast-enhanced  ultrasound,  and  most  often  present  in
MRI.  The  degree  of  differentiation  of  the  HCC  also  plays  a
role,  the  classic  features  being  most  frequently  absent  in
well-differentiated  HCCs  [9,14].
These  enhancement  characteristics  can  however  be
present  in  one  type  of  imaging  examination  and  not  in
another,  without  there  being  any  clear  explanation  for  this.
The  ﬁrst  solution  to  overcome  the  lack  of  characteris-
tic  appearance  of  a  nodule  discovered  during  an  imaging
examination  is  therefore  to  widen  the  range  of  exploration
techniques.  While  contrast-enhanced  ultrasound  is  rarely
positive  (about  40%  according  to  our  own  as  yet  unpublished
data),  the  use  of  CT  or  MRI  in  turn,  when  one  or  other  of  the
two  techniques  is  negative,  markedly  increases  imaging  sen-
sitivity  for  the  diagnosis  of  small  HCC.  The  study  by  Sersté
et  al.  [10]  thus  reported  sensitivity  of  74%  for  CT  for  show-
ing  the  typical  vascular  kinetics  and  81%  for  MRI,  and  when
one  or  the  other  technique  is  used  in  turn,  sensitivity  reaches
98%  (Fig.  2).  Using  CT  and  MRI  in  turn  is  the  approach  recom-
mended  in  the  guidelines  of  the  European  Association  for  the
f
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Table  1  Sensitivity  (%)  of  imaging  examinations  for  the  diag
AASLD  criteria  (arterial  hypervascularisation  and  portal  and/or
Maximum  size  (cm)  
Forner  et  al.  [12] 2  
Leoni  et  al.  [11] 3  
Sestré  et  al.  [10] 2  
Rimola  et  al.  [27]  2  
Aubé  (unpublished  data)  3  
AASLD: American Association for the Study of Liver Diseases. HCC  699
tudy  of  the  Liver  (EASL)  and  the  American  Association  for
he  Study  of  Liver  Diseases  (AASLD).  It  should  be  noted  that
n  these  recommendations,  even  though  contrast-enhanced
ltrasound  may  still  provide  a  diagnostic  pointer,  its  use  can
o  longer  conﬁrm  the  diagnosis  and  defer  a  biopsy.  Only  CT
nd  MRI  are  authorised  for  providing  a  non-invasive  diagnosis
ith  certainty  [3,8].
Hyperintensity  with  T2-weighting  is  another  feature  in
he  diagnosis  of  small  HCCs  (Fig.  3).  In  making  a  diagnosis
f  HCC  for  lesions  measuring  less  than  20  mm,  if  the  pres-
nce  of  typical  vascular  kinetics  and/or  T2  hyperintensity  is
onsidered,  the  sensitivity  of  MRI  is  79.4%  and  its  speciﬁcity
6.9%,  whereas  if  typical  vascular  kinetics  are  considered
lone,  the  sensitivity  of  MRI  is  only  67.6%,  with  identical
peciﬁcity  [15].
The  use  of  diffusion  imaging  is  also  an  important  element
or  positive  diagnosis  of  HCC,  since  more  than  75%  of  small
CCs  are  hyperintense  in  diffusion-weighted  imaging  [9,10].
owever,  there  does  not  seem  to  be  any  correlation  between
iffusion  hyperintensity  and  tumour  differentiation.
The  performance  of  diffusion  hyperintensity  alone  (with-
ut  the  typical  enhancement  kinetics)  is  still  being  discussed
n  the  literature.  One  team  [16]  has  shown  that  diffusion-
eighted  imaging  performs  better  for  diagnosis  of  small
CC  than  typical  appearance  (arterial  enhancement  and
ortal  and/or  late  washout)  recognised  by  the  guide-
ines;  another  team  could  not  conﬁrm  these  results
17].
Even  if  they  are  still  controversial,  it  is  important  to
eport  the  results  of  Piana  et  al.  [16]:  for  the  diagnosis  of
CC  of  less  than  2  cm,  the  use  of  the  combination  comprised
f  arterial  hypervascularisation  +  diffusion-weighted  hyper-
ntensity  instead  of  arterial  hypervascularisation  +  lesion
ashout  increases  the  sensitivity  of  MRI  for  diagnosing  small
CCs  from  60%  to  77%,  while  with  joint  use  of  the  two
ombinations  (arterial  hypervascularisation  +  lesion  washout
nd  +  diffusion-weighted  hyperintensity)  sensitivity  is  85%
Fig.  4).
It  should  be  made  clear  that  in  diffusion-weighted  imag-
ng,  there  is  no  place  for  measurement  of  apparent  diffusion
oefﬁcient  (ADC)  values  in  the  diagnosis  of  small  HCC.
Liver-speciﬁc  contrast  agents,  ﬁxed  by  the  hepatocytes
nd  responsible  for  enhancement  of  the  parenchyma  in  the
ate  phase  (known  as  the  hepatocytic  phase)  —  after  20  min
or  the  most  recent  product  (gadoxetate  disodium)  —  appear
o  increase  detection  of  small  hepatocellular  carcinomas
18,19],  and  the  ability,  in  particular,  to  differentiate  early
CC  from  dysplastic  nodules:  in  97%  of  cases  early  HCC  is  not
nosis  of  small  hepatocellular  carcinoma  according  to  the
 late  phase  washout).
Contrast-enhanced  ultrasound  CT  MRI
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Figure 2. The usefulness of alternative imaging if the lesion is atypical. Monitoring examination for cirrhosis of exogenous and metabolic
origin. CT scan in the arterial (a) and portal (b) phases: the lesion is hardly visible in the arterial phase and does not wash out in the
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portal phase (circle). T1-weighted MRI with fat saturation in the a
ypervascular in the arterial phase with washout of the lesion.
nhanced  in  the  hepatocytic  phase,  whereas  100%  of  dys-
lastic  nodules  are  iso-  or  hyperintense  in  the  hepatocytic
hase  [20]  (Fig.  5).
ypovascular  small  hepatocellular  carcinoma
mall  HCCs  and  well-differentiated  HCCs  are  less  often
ypervascular  than  larger  HCCs  [9,21,22].  17%  of  HCC
esions  measuring  less  than  2  cm  are  reported  to  be  hypo-
ascular  [23].  It  is  difﬁcult  to  imagine  a  tumour,  which
s  not  enhanced  in  the  arterial  phase  being  a  hepato-
ellular  carcinoma,  irrespective  of  the  signs  associated
ith  it  (Fig.  6).  In  these  circumstances,  a  biopsy  must  be
erformed.
The  problem  of  hypovascular  HCCs  can  be  associated
ith  fat-containing  HCCs.  Fat  content  is  highly  sugges-
ive  of  HCC  in  the  context  of  cirrhosis,  but  other  tumours
ith  a  fat  content  (adenoma,  angiomyolipoma,  etc.)  can-
ot  be  formally  ruled  out  [24].  Apart  from  the  fact
hat  fat  is  present,  arterial  hypervascularisation  remains
oderate  or  non-existent  and  lesion  washout  cannot  be
etected.  Non-invasive  diagnosis  following  the  interna-
ional  recommendations  cannot  therefore  be  made  in
hese  cases  (Fig.  7).  The  frequency  of  these  fatty  HCCs
mong  small  (less  than  2  cm)  HCCs  has  been  reported  as
2%  [9].
t
e
(l (c) and portal (d) phases: the nodule has a typical appearance,
seudotumours
n  chronic  liver  disease,  the  two  pseudotumours  that  will
ose  problems  for  differential  diagnosis  with  small  HCC
re  vascular  disorders,  particularly  arterioportal  ﬁstulas  and
onﬂuent  ﬁbrosis.  These  abnormalities  have  quite  charac-
eristic  radiological  signs,  which  usually  allow  them  to  be
ecognised.
In  liver  cirrhosis,  micro-emboli  of  the  portal  vasculature
re  frequently  associated  with  arterioportal  ﬁstulas,  in  the
bsence  of  any  tumour.
They  are  typically  well  deﬁned,  sub-capsular,  enhanced
n  the  arterial  phase,  then  becoming  homogeneous  with  the
djacent  parenchyma  in  the  portal  phase.
However,  in  some  cases  they  can  acquire  a  nodular
ppearance,  while  usually  remaining  peripheral.  In  addition,
hey  can  maintain  a  positive  contrast  gradient  in  the  por-
al  phase  [25]. They  are  only  visible  on  injected  sequences
nd  are  not  seen  without  contrast  injection,  whatever  MRI
equence  is  used  (Fig.  8).
Conﬂuent  ﬁbrosis  is  often  larger.  It  frequently  has  a
eripheral  starting  point,  accompanied  by  retraction  of
he  capsule.  It  appears  hyperintense  with  T2-weighting,
nhances  gradually  and  is  mainly  visible  in  the  late  phases
after  3  min)  (Fig.  9).
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Figure 3. The usefulness of T2-weighting. Monitoring examination for cirrhosis of exogenous origin. T1-weighted MRI with fat saturation
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pafter gadolinium injection in the arterial (a), portal (b) and late (c)
in the arterial phase after injection, without washout of the lesion i
Other tumours
While  the  appearance  of  a  nodule  in  liver  cirrhosis  should  in
the  ﬁrst  instance  suggest  HCC,  other  tumours  can  be  encoun-
tered  in  a  cirrhotic  liver.
Some  are  hypovascular  (peripheral  cholangiocarci-
noma,  metastasis),  and  will  not  therefore  immediately
suggest  a  hepatocellular  carcinoma;  others,  hypervascu-
lar  in  the  arterial  phase  (hypervascular  haemangioma,
adenoma,  focal  nodular  hyperplasia),  will  be  the  dif-
ferential  diagnoses  for  an  atypical  small  HCC.  Dysplas-
tic  nodules  may  appear  to  be  very  similar  to  small
HCC.
Peripheral  cholangiocarcinoma  is  a  tumour  promoted
by  cirrhosis.  Hypervascularisation  in  the  arterial  phase
is  rare,  but  possible.  It  has  been  reported  recently
that  intrahepatic  cholangiocarcinomas  in  liver  cirrhosis
were  more  hypervascularised  than  those  occurring  in
non-cirrhotic  livers  [26].  In  this  case  washout  may  be
present.
i
u
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nes, and with T2-weighting (d): hepatocellular carcinoma enhanced
 portal and late phases, but with hyperintensity with T2-weighting.
However,  the  appearance  of  a  peripheral  cholangiocar-
inoma  is  usually  of  a tumour  with  slow,  often  incomplete,
eripheral  enhancement  (Fig.  10)  [27,28].
Hypervascular  haemangiomas  are  common.  In  the  arte-
ial  phase,  their  appearance  can  be  perfectly  attributed  to
 small  HCC  (Fig.  11),  but  there  is  no  lesion  washout.  On  the
ontrary,  the  lesion  tends  to  retain  the  contrast  agent  in  the
nterstitial  phase,  the  enhancement  kinetics  being  the  same
s  that  of  large  arteries  such  as  the  aorta.  Another  pointer  is
he  evident  arterial  hypervascularisation  of  the  parenchyma
round  the  nodule.  In  the  end,  the  convincing  argument
s  provided  by  deﬁnite  hyperintensity  in  a  T2-weighted  MR
mage  [29].
There  can  also  be  focal  nodular  hyperplasia  in  a  cirrhotic
iver.  With  the  exception  of  lesion  washout,  its  appearance
erfectly  mimics  the  appearance  of  an  HCC  (Fig.  12).  Hyper-
ntensity  with  T2  and  diffusion-weighting  is  possible.  The
se  of  a liver-speciﬁc  contrast  agent  showing  FNH  ﬁxation
nd  the  absence  of  ﬁxation  by  HCC  could  be  a  means  of
on-invasive  diagnosis  [30,31].
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Figure 4. The usefulness of diffusion-weighted sequences. Monitoring examination for HBV cirrhosis. T1-weighted MRI with fat saturation
after gadolinium injection in the arterial (a), portal (b) and late (c) phases and with diffusion-weighting (d): hepatocellular carcinoma
enhanced in the arterial phase after injection, without washout of the lesion in the portal and late phases, but with hyperintensity with
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Dysplastic  nodules  are  often  hypervascular  in  the  arte-
ial  phase:  a  recent  study  [15]  showed  this  to  be  the  case
n  63%  of  them.  In  the  same  study,  lesion  washout  was
resent  in  16%  of  cases.  However,  dysplastic  nodules  are
ot  generally  hyperintense  with  T2  or  diffusion-weighting.
ixation  of  the  liver-speciﬁc  contrast  agent  in  the  hep-
tocytic  phase  has  been  reported  as  constant  [20].  The
d
u
c
[volution  of  dysplastic  nodules  has  been  little  studied  in  the
iterature,  and  their  current  management  is  often  little  dif-
erent  from  management  of  HCC,  but  they  do  not  seem  to
evelop  systematically  into  HCC  [13].  In  this  context,  the
se  of  gadoxetic  acid  currently  appears  to  be  the  most  efﬁ-
ient  technique  for  differentiating  between  these  lesions
20].
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Figure 5. The usefulness of liver-speciﬁc contrast agents. T1-weighted MRI without (a) then after injection of gadoxetic acid in the
arterial (b), portal (c) and hepatobiliary (d) phases. Hepatocellular carcinoma of the left lobe of the liver (arrow), enhanced in the arterial
phase, without lesion washout and no ﬁxation of the contrast agent in the hepatobiliary phase.
Images from Myeon-Jin Kim (MD), Seoul, Republic of Korea.
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Figure 6. Hypovascular hepatocellular carcinoma (HCC). Monitoring examination for cirrhosis of exogenous origin. T1-weighted MRI with
fat saturation in the arterial (a) portal (b) phases and diffusion-weighted sequence (c). The HCC is hypovascular but hyperintense in the
diffusion-weighted sequence (arrow).
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Figure 7. Hepatocellular carcinoma with a fatty component. Monitoring examination for cirrhosis of metabolic origin. T1-weighted MRI in
phase (a) and out of phase (b): out-of-phase fall in signal indicating its fat content. T1-weighted image with fat saturation after gadolinium
injection in the arterial (c) and portal (d) phases: enhanced in the arterial phase with lesion washout accentuated by the fat content.
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Figure 8. Arterioportal ﬁstula. Monitoring examination for cirrhosis of exogenous origin. CT scan without (a) and after injection of an
iodinated contrast agent in the arterial (b), portal (c) and late (d) phases: small peripheral arterioportal ﬁstula (arrow) spontaneously
isodense (a), responsible for parenchymal enhancement from the arterial phase, and which became homogeneous in the portal and late
phases.
Figure 9. Peripheral conﬂuent ﬁbrosis. Monitoring examination for cirrhosis of exogenous and metabolic origin. T2-weighted (a) and T1-
weighted MRI with fat saturation in the arterial (b) and late (c) phases: peripheral conﬂuent ﬁbrosis with capsule retraction (arrow) with
T2-weighted hyperintensity, with no enhancement in the arterial phase but gradually enhancing in the late phase (after 3 min).
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Figure 10. Cholangiocarcinoma. Monitoring examination for cirrhosis of exogenous origin. CT scan without (a) and after injection of an
iodinated contrast agent in the arterial (b), portal (c) and late (d) phases: peripheral cholangiocarcinoma of the tip of the left lobe of the
liver (arrow), spontaneously hypodense, without arterial hypervascularisation, with incomplete peripheral enhancement in the late phase
(d).
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Figure 11. Haemangioma. Monitoring examination for cirrhosis of viral origin. T1-weighted MRI with fat saturation without (a), then after
gadolinium injection in the arterial (b) and portal (c) phases and with T2-weighting (d). Hypervascular lesion in the arterial phase, with
persistent enhancement in the portal phase. Note the parenchymal enhancement around the lesion in the arterial phase due to high arterial
ﬂow. The clear hyperintensity with T2-weighting conﬁrms the diagnosis of haemangioma.
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Figure 12. Focal nodular hyperplasia (FNH). Monitoring examination for cirrhosis of viral origin. T1-weighted MRI with fat saturation
after gadolinium injection in the arterial (a), portal (b), late (c) phases and with diffusion-weighting (d): focal nodular hyperplasia (arrow),
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logical  examination  of  its  appearance.  If  a  certain  diagnosis
of  HCC  or  another  lesion  cannot  be  made  with  imaging,  a
biopsy  must  be  performed  without  fail.
TAKE-HOME  MESSAGES
• Six-monthly  ultrasound  monitoring  of  patients  with
cirrhosis  should  lead  to  the  detection  of  small  HCCs.
• Non-invasive  diagnosis  of  HCC  in  cirrhotic  patients  is
possible  using  CT  and/or  MRI.
• The  characteristic  appearance  of  HCC  is  arterial
hypervascularisation  followed  by  lesion  washout  in
the  portal  and/or  late  phase.
• Small  HCCs  have  an  atypical  CT  or  MRI  appearance  inenhanced in the arterial phase with persistence of the enhanceme
late phase is visible helping to suggest a diagnosis of FNH. Note the
Conclusion
The  diagnosis  of  small  HCC  poses  two  major  difﬁculties.
Firstly,  the  typical  vascular  kinetics  of  HCC  allowing  it  to  be
diagnosed  non-invasively  are  often  absent.  Secondly,  lesions
that  can  mimic  HCC  (an  arterioportal  ﬁstula,  conﬂuent  ﬁbro-
sis,  a  hypervascular  haemangioma,  benign  hepatocellular
tumours,  etc.)  are  often  small  and  they  appear  similar  to
an  atypical  small  HCC.
There  are  two  broad  solutions  to  the  problem:  ﬁrst  of  all,
widen  the  range  of  examinations.  This  increases  the  possibil-
ity  of  detecting  the  characteristic  vascular  kinetics  of  HCC.
Secondly,  signs  other  than  those  provided  by  the  vascular
kinetics  must  be  used,  namely  from  T2  and  diffusion-
weighting,  and  liver-speciﬁc  contrast  agents.  In  some  cases
these  tools  will  provide  differential  diagnoses  (conﬂuent
ﬁbrosis,  hypervascular  haemangioma,  benign  hepatocellular
tumour).  In  other  cases  they  will  strengthen  the  suspicion  of
HCC.It  is  possible  (and  without  doubt  desirable)  that  in  the
future  these  solutions  will  form  part  of  the  algorithm  for
non-invasive  diagnosis  of  HCC  in  a  cirrhotic  liver. the portal and late phases. A small central area enhanced in the
eading hyperintensity of the lesion with diffusion-weighting.
It  is  important  to  remember  that,  whatever  the  diagnos-
ic  tools  used,  whenever  a  tumour  is  discovered  in  a  cirrhotic
iver,  even  (and  particularly)  if  it  is  small,  our  attitude  should
ot  be  to  monitor  its  evolution  but  to  make  a  careful  radio-20  to  50%  of  cases.
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• In the  absence  of  the  characteristic  appearance  of
HCC  in  one  examination  (CT  or  MRI)  the  other  type
of  examination  should  be  carried  out.
• The  use  of  diffusion-weighted  and  T2-weighted
imaging  and  liver-speciﬁc  contrast  agents  can  help  in
the  diagnosis  of  small  HCCs,  but  these  methods  are
not  yet  recognised  by  the  guidelines  as  non-invasive
diagnostic  tools.
• Lesions  other  than  HCC  occur  in  the  cirrhotic  liver:
a  hypervascular  nodule  is  not  necessarily  HCC,  and  a
hypovascular  nodule  does  not  eliminate  HCC.
• If  the  characteristic  appearance  of  HCC  is  not  seen
in  imaging,  a  biopsy  must  be  performed.
C
T
o
f
a
T2-weighted  (Fig.  13a)  and  T1-weighted  MRI  after  injection
of  gadolinium  with  acquisition  in  the  arterial  (Fig.  13b)  and
portal  phases  (Fig.  13c)  was  performed  to  characterise  the
nodule.
F
a
igure 13. T2-weighted sequence with fat saturation (a), T1-weigh
cquisition in the arterial (b) and portal (c) phases.V.  Cartier,  C.  Aubé
linical case
his  58-year-old  patient  was  being  monitored  for  cirrhosis
f  exogenous  origin:  he  had  been  weaned  from  the  cause
or  5  years.  During  the  six-monthly  ultrasound  monitoring,
 16  mm  nodule  was  discovered  in  the  left  lobe  of  the  liver.ted sequence with fat saturation after gadolinium injection and
mall
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[Gastrointestinal  imaging:  Tips  and  traps  in  the  diagnosis  of  s
Questions
1.  Why  can  we  not  make  the  diagnosis  of  HCC?
2.  What  do  you  do  in  practice?
3.  Is  there  a  feature  on  one  of  these  sequences,  which  could
point  towards  a  diagnosis  of  HCC?
4.  If  you  cannot  make  a  diagnosis  with  imaging,  what  would
you  recommend  for  this  patient?
Answers
1.  No  diagnosis  of  HCC  can  be  made  because  there  is  no
lesion  washout.
2.  Another  type  of  examination  should  be  performed  (CT
scan)  as  recommended  by  the  guidelines  for  non-invasive
diagnosis  of  HCC.
3.  The  hyperintensity  with  T2-weighting  suggests  HCC,  but
cannot  be  considered  to  positively  conﬁrm  it  according
to  the  current  guidelines.
4.  A  biopsy  is  essential;  simply  monitoring  the  lesion  is  not
acceptable.
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